These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 35192139)

  • 41. Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?
    Ben-Shmuel A; Biber G; Barda-Saad M
    Front Immunol; 2020; 11():275. PubMed ID: 32153582
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma.
    Chen H; Molberg K; Strickland AL; Castrillon DH; Carrick K; Jiang Q; Niu S; Rivera-Colon G; Gwin K; Hinson S; Lea J; Miller DS; Zheng W; Lucas E
    Am J Surg Pathol; 2020 Aug; 44(8):1050-1060. PubMed ID: 32384321
    [TBL] [Abstract][Full Text] [Related]  

  • 43. WNT signaling inducing activity in ascites predicts poor outcome in ovarian cancer.
    Kotrbová A; Ovesná P; Gybel' T; Radaszkiewicz T; Bednaříková M; Hausnerová J; Jandáková E; Minář L; Crha I; Weinberger V; Záveský L; Bryja V; Pospíchalová V
    Theranostics; 2020; 10(2):537-552. PubMed ID: 31903136
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Clinicopathological study of SET subtype of ovarian high-grade serous carcinoma].
    Sun YW; Shen DH; Cui SS; He HJ; Zhang XL; Wang W; Liu CR
    Zhonghua Fu Chan Ke Za Zhi; 2019 Sep; 54(9):595-600. PubMed ID: 31550775
    [No Abstract]   [Full Text] [Related]  

  • 45. Profile of differentially expressed miRNAs in high-grade serous carcinoma and clear cell ovarian carcinoma, and the expression of miR-510 in ovarian carcinoma.
    Zhang X; Guo G; Wang G; Zhao J; Wang B; Yu X; Ding Y
    Mol Med Rep; 2015 Dec; 12(6):8021-31. PubMed ID: 26497752
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Outcomes of Non-High Grade Serous Carcinoma after Neoadjuvant Chemotherapy for Advanced-Stage Ovarian Cancer: Single-Institution Experience.
    Chung YS; Lee JY; Kim HS; Nam EJ; Kim SW; Kim YT
    Yonsei Med J; 2018 Oct; 59(8):930-936. PubMed ID: 30187699
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting IDH1 as a Prosenescent Therapy in High-grade Serous Ovarian Cancer.
    Dahl ES; Buj R; Leon KE; Newell JM; Imamura Y; Bitler BG; Snyder NW; Aird KM
    Mol Cancer Res; 2019 Aug; 17(8):1710-1720. PubMed ID: 31110157
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mechanisms of NK cell dysfunction in the tumor microenvironment and current clinical approaches to harness NK cell potential for immunotherapy.
    Devillier R; Chrétien AS; Pagliardini T; Salem N; Blaise D; Olive D
    J Leukoc Biol; 2021 Jun; 109(6):1071-1088. PubMed ID: 32991746
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Multi-omics in high-grade serous ovarian cancer: Biomarkers from genome to the immunome.
    Clifford C; Vitkin N; Nersesian S; Reid-Schachter G; Francis JA; Koti M
    Am J Reprod Immunol; 2018 Aug; 80(2):e12975. PubMed ID: 29781548
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recurrent BCAM-AKT2 fusion gene leads to a constitutively activated AKT2 fusion kinase in high-grade serous ovarian carcinoma.
    Kannan K; Coarfa C; Chao PW; Luo L; Wang Y; Brinegar AE; Hawkins SM; Milosavljevic A; Matzuk MM; Yen L
    Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1272-7. PubMed ID: 25733895
    [TBL] [Abstract][Full Text] [Related]  

  • 51. NK Cells in the Tumor Microenvironment.
    Guillerey C
    Adv Exp Med Biol; 2020; 1273():69-90. PubMed ID: 33119876
    [TBL] [Abstract][Full Text] [Related]  

  • 52. γ-Glutamyl cyclotransferase contributes to tumor progression in high grade serous ovarian cancer by regulating epithelial-mesenchymal transition via activating PI3K/AKT/mTOR pathway.
    Li Y; Wu T; Wang Y; Yang L; Hu C; Chen L; Wu S
    Gynecol Oncol; 2018 Apr; 149(1):163-172. PubMed ID: 29429592
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy.
    Gaggero S; Witt K; Carlsten M; Mitra S
    Front Immunol; 2020; 11():621225. PubMed ID: 33584718
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reactivity of NK Cells Against Ovarian Cancer Cells Is Maintained in the Presence of Calcium Phosphate Nanoparticles.
    Hrvat A; Schmidt M; Obholzer M; Benders S; Kollenda S; Horn PA; Epple M; Brandau S; Mallmann-Gottschalk N
    Front Immunol; 2022; 13():830938. PubMed ID: 35251021
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cells.
    Uppendahl LD; Felices M; Bendzick L; Ryan C; Kodal B; Hinderlie P; Boylan KLM; Skubitz APN; Miller JS; Geller MA
    Gynecol Oncol; 2019 Apr; 153(1):149-157. PubMed ID: 30658847
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of clinical behavior between mucinous ovarian carcinoma with infiltrative and expansile invasion and high-grade serous ovarian carcinoma: a retrospective analysis.
    Hada T; Miyamoto M; Ishibashi H; Matsuura H; Kakimoto S; Iwahashi H; Tsuda H; Takano M
    Diagn Pathol; 2022 Jan; 17(1):12. PubMed ID: 35057833
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cancer immunosurveillance and immunoediting by natural killer cells.
    Gross E; Sunwoo JB; Bui JD
    Cancer J; 2013; 19(6):483-9. PubMed ID: 24270347
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Differential expression of immune related genes in high-grade ovarian serous carcinoma.
    Siamakpour-Reihani S; Cobb LP; Jiang C; Zhang D; Previs RA; Owzar K; Nixon AB; Alvarez Secord A
    Gynecol Oncol; 2020 Mar; 156(3):662-668. PubMed ID: 31918995
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Metabolic Markers and Statistical Prediction of Serous Ovarian Cancer Aggressiveness by Ambient Ionization Mass Spectrometry Imaging.
    Sans M; Gharpure K; Tibshirani R; Zhang J; Liang L; Liu J; Young JH; Dood RL; Sood AK; Eberlin LS
    Cancer Res; 2017 Jun; 77(11):2903-2913. PubMed ID: 28416487
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer.
    Cao B; Liu M; Wang L; Liang B; Feng Y; Chen X; Shi Y; Zhang J; Ye X; Tian Y; Zhi C; Li J; Lian H; Wu Q; Zhang Z
    Biochem Biophys Res Commun; 2020 Mar; 524(1):96-102. PubMed ID: 31980173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.